Skip to content

Advertisement

  • Research note
  • Open Access

Identification of cyclic hexapeptides natural products with inhibitory potency against Mycobacterium tuberculosis

  • 1, 4,
  • 2,
  • 2,
  • 2,
  • 2,
  • 2,
  • 2,
  • 3,
  • 3,
  • 1,
  • 1 and
  • 2Email authorView ORCID ID profile
BMC Research Notes201811:416

https://doi.org/10.1186/s13104-018-3526-z

  • Received: 14 May 2018
  • Accepted: 20 June 2018
  • Published:

Abstract

Objective

Our aim was to identify natural products with anti-tubercular activity.

Results

A set of ~ 500 purified natural product compounds was screened for inhibition against the human pathogen Mycobacterium tuberculosis. A series of cyclic hexapeptides with anti-tubercular activity was identified. Five analogs from a set of sixteen closely related compounds were active, with minimum inhibitory concentrations ranging from 2.3 to 8.9 μM. Eleven structural analogs had no significant activity (MIC > 20 μM) demonstrating structure activity relationship. Sequencing of resistant mutant isolates failed to identify changes accounting for the resistance phenotype.

Keywords

  • Mycobacteria
  • Antibacterial
  • Natural product
  • Anti-tubercular
  • Antibiotic resistance

Introduction

Tuberculosis remains a global health problem, with an increasing number of new cases (10.4 million in 2015) and an increasing problem of drug resistance [1]. New therapeutic agents which act against novel bacterial targets are needed to supplement and supplant the current drugs. Therefore there is great interest in finding new chemical matter that has activity against the causative agent, Mycobacterium tuberculosis. A large effort has been expended to examine small molecule libraries as starting point for drug discovery [2, 3]. Less attention has been paid to natural products as starting points for a discovery program. We were interested in expanding chemical diversity to identify novel inhibitors which could be used either as starting points for a drug discovery program or as probes to identify novel targets.

Main text

A phenotypic screen to identify compounds with activity against M. tuberculosis using the MSD collection of purified natural products was initiated. A small set (~ 500) of natural products for activity against M. tuberculosis H37Rv-LP (ATCC 25618) expressing a red fluorescent protein were tested [46]. Compounds were tested at a single concentration of 20 µM. Growth was measured by fluorescence after 5 days of aerobic culture in Middlebrook 7H9 medium supplemented with 10% v/v OADC (oleic acid, albumin, d-glucose, catalase; Becton–Dickinson) and 0.05% w/v Tween 80 at 37 °C in 384-well plates. Growth inhibition was calculated with reference to controls (DMSO only). Within this screen, hits were defined as having > 30% inhibition of growth. Hits were confirmed by testing compounds in a dose response, using two readouts for growth—OD590 and fluorescence (Ex 560/Em 590) [46]. Compounds were solubilized in DMSO, and a ten point, twofold serial dilution prepared in DMSO. M. tuberculosis was cultured in Middlebrook 7H9 supplemented with 10% v/v OADC and 0.05% w/v Tween 80. Cultures were inoculated at a final OD590 of 0.02 into 96-well plates containing compounds (final DMSO concentration of 2%). The starting concentration for compounds was 20 µM. Growth inhibition curves were plotted using the Levenberg–Marquardt algorithm and the concentration that resulted in 90% inhibition of growth was determined (MIC90). For active compounds, assays were conducted at least twice. Rifampicin was used as a control in each plate—for comparison the MIC of rifampicin was 0.0077 µM.

From these experiments, MSD-453 confirmed as a hit and further analogs based on similarity searches were ordered and tested. The initial hit, a cyclic hexapeptide, cyclo[N-(Me)Phe-Pro-Phe-N-(OH)Leu-Piz-Piz] (compound 1) had good activity against M. tuberculosis, with an MIC90 of 2.3 µM (Table 1). Several natural congeners (24) and semi-synthetic and synthetic analogs (516) were available from the MSD sample library and were tested for activity against replicating M. tuberculosis under aerobic conditions in liquid medium. Structural identities and purity of the compounds were verified prior to anti-tubercular testing. Four other analogs (25) exhibited intermediate inhibitory potencies (MIC90 of 2.8–8.9 μM), whereas eleven compounds (616) showed no inhibitory activity (MIC90 > 20 µM).
Table 1

Activity of cyclic peptides against M. tuberculosis

Compound number

Structure

Synonym

MIC90

1

MSD-045

2.3 ± 0.5

2

MSD-524

2.8 ± 0.8

3

MSD-099

8.9 ± 1.8

4

MSD-135

7.3 ± 1.9

5

MSD-2980

8.2 ± 1.2

6

MSD-695

> 20

7

MSD-408

> 20

8

MSD-196

> 20

9

MSD-818

> 20

10

MSD-109

> 20

11

MSD-810

> 20

12

MSD-008

> 20

13

MSD-369

> 20

14

MSD-229

> 20

15

MSD-049

> 20

16

MSD-064

> 20

MIC90 were determined against aerobically-cultured M. tuberculosis in liquid culture after 5 days of growth [5]. Growth inhibition curves were plotted using the Levenberg–Marquardt algorithm and the concentration that resulted in 90% inhibition of growth was determined (MIC90). MIC90 were determined a minimum of two times for active compounds. Data are average ± standard deviation

Although the dataset of compounds tested are limited, some elements of the structure–activity relationship (SAR) (Fig. 1) have been determined. Replacement of the N-hydroxyleucine with N-hydroxyisoleucine resulted in similar activity (2, MIC90 = 2.8 µM). Replacement of the phenylalanine with a valine reduced the activity slightly by three to fourfold (3, MIC90 = 8.9 µM). Similar reduced activity was seen after a double substitution of N-methylphenylalanine and phenylalanine with isoleucine and leucine (4, MIC90 = 7.3 µM). An N-alkyl-ketone in place of N-hydroxyleucine was tolerated, but reduced the biological activity by threefold (5, MIC90 = 8.2 µM), demonstrating that the N-hydroxyl group at that position is not critical. In contrast, the piperazic acids (Piz) were critical for activity of the molecule, since several tetrahydropiperazic (∆Piz) acid derivatives (612) and the pipecolic acid (Pip) (13 and 15) analog resulted in loss of anti-tubercular activity. O-Alkylation of the N-hydroxyleucine with an acetic acid or acetic acid ester abrogated activity (1314). The combined replacement of N-methylphenylalanine with norvaline and phenylalanine with leucine also removed activity (16, MIC90 > 20 μM). Based on these analogs, we were able to determine some limited structure–activity relationship (Fig. 1). Although the compounds were not as potent as rifampicin, they did have good activity, with a dynamic SAR ranging from low micromolar to inactive (> 20 µM).
Fig. 1
Fig. 1

M. tuberculosis cyclic hexapeptide structure-activity relationship. N–OH-Leu, N-hydroxyleucine; N–OH-Ile, N-hydroxyisoleucine; Phe, phenylalanine; Val, valine; N-Me-Phe, N-methylphenylalanine; Ile, isoleucine; Leu, leucine; Piz, piperazic acid; ∆Piz tetrahydropiperazic acid; Pip, pipecolic acid; N-Me-Nor Val, N-methyl-norvaline

The original hit molecule, MSD-453, along with several congeners [710] and synthetic analogs [812], were originally identified as sub-micromolar to low nanomolar oxytocin receptor antagonists. M. tuberculosis does not have a homolog of this receptor; thus, this series appears to have a different target in the pathogen.

In an attempt to identify the M. tuberculosis biochemical target, resistant mutants to two of the compounds were isolated. The potency of each compound on Middlebrook 7H10 medium containing 10% v/v OADC supplement was measured. MIC99 values were determined by the serial proportion method and defined as the minimum concentration required to prevent 99% growth on solid medium [13]. Under these incubation conditions, the MIC99 was 1.6 and 0.8 µM for MSD-045 and MSD-099 respectively (Table 2). Resistant mutants were isolated on Middlebrook 7H10 plus 10% v/v OADC at 5X MIC of each compound after 3–4 weeks growth [14]. Colonies were tested for MIC99 on solid medium to confirm resistance (Table 2). In this longer term assay on solid media both compounds showed better potency than when tested for shorter time (5 days) assay in liquid media (Table 1). Although nine confirmed resistant isolates were subjected to whole genome sequencing [15], no mutations were observed in 8 of the strains. Strain LP-0458686-RM1 had two mutations, one in gap (Rv1436) and one in Rv1543, but these were not observed in any of the other eight strains. Thus no genotypic explanation for the observed resistance was determined. In this case, the resistance phenotype could be due to epigenetic phenomena.
Table 2

M. tuberculosis strains resistant to hexapeptide inhibitor compounds

Strain

Compound

MIC99 (µM)

WT

MSD-045

1.6

LP-0458690-RM1

MSD-045

13

LP-0458690-RM2

MSD-045

25

LP-0458690-RM3

MSD-045

25

LP-0458690-RM4

MSD-045

25

LP-0458690-RM5

MSD-045

25

LP-0458690-RM6

MSD-045

25

WT

MSD-099

0.8

LP-0458686-RM1

MSD-099

3.1

LP-0458686-RM2

MSD-099

3.1

LP-0458686-RM3

MSD-099

3.1

MIC99 were determined against M. tuberculosis resistant isolates on solid medium after 3–4 weeks. MIC99 was determined by the serial proportion method and defined as the minimum concentration required to prevent 99% growth [13]

In conclusion, a series of cyclic natural product peptides with activity against M. tuberculosis, which could form the basis of further exploratory work including target identification, are disclosed. Future work to identify the intracellular target would assist in further development of this class of molecules.

Limitations

  • No in vivo activity is reported yet.

  • The mode of resistance is not yet understood.

  • The target for the series is not known.

Abbreviations

OADC: 

oleic acid, albumin, d-glucose, catalase

MIC: 

minimum inhibitory concentration

SAR: 

structure–activity relationship

Piz: 

piperazic acid

Pip: 

pipecolic acid

Declarations

Authors’ contributions

Experimental design: SBS, JO, MAB, BS, AK, TOM, YO, TRI, KY, DBO, TP. Experimental work: MAB, BS, AK, TOM, YO, TRI. Data analysis: SBS, JO, MAB, BS, AK, TOM, YO, TRI, JCS, KY, DBO, TP. Writing manuscript: SBS. DBO, TP. Reviewing manuscript: All authors. All authors read and approved the final manuscript.

Acknowledgements

We thank James Ahn and Juliane Ollinger for technical assistance. This work was carried out under the auspices of the TB Drug Accelerator consortium.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Funding

This work was supported in part by funding from the Bill and Melinda Gates Foundation under grant OPP1024038.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Merck & Co., Inc., Infectious Diseases, 770 Sumneytown Pike, West Point, PA 19486, USA
(2)
TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue E, Suite 400, Seattle, WA 98102, USA
(3)
Texas A&M University, College Station, TX, USA
(4)
Present address: SBS Pharma Consulting LLC, Edison, NJ 08820, USA

References

  1. WHO. Global tuberculosis report 2017. ISBN 978-92-4-156551-6. 2017. http://www.who.int/tb/publications/global_report/en/. Accessed 22 June 2018.
  2. Kumar A, Chettiar S, Parish T. Current challenges in drug discovery for tuberculosis. Expert Opin Drug Discov. 2017;12:1–4.View ArticlePubMedGoogle Scholar
  3. Zuniga E, Early J, Parish T. The future for early stage tuberculosis drug discovery. Future Microbiol. 2015;10:217–29.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Carroll P, Schreuder LJ, Muwanguzi-Karugaba J, Wiles S, Robertson BD, Ripoll J, Ward TH, Bancroft GJ, Schaible UE, Parish T. Sensitive detection of gene expression in mycobacteria under replicating and non-replicating conditions using optimized far-red reporters. PLoS ONE. 2010;5:e9823.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Ollinger J, Bailey MA, Moraski GC, Casey A, Florio S, Alling T, Miller MJ, Parish T. A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis. PLoS ONE. 2013;8:e60531.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Zelmer A, Carroll P, Andreu N, Hagens K, Mahlo J, Redinger N, Robertson BD, Wiles S, Ward TH, Parish T, Ripoll J, Bancroft GJ, Schaible UE. A new in vivo model to test anti-tuberculosis drugs using fluorescent imaging. J Antimicrob Chemother. 2012;67:1948–60.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Goetz MA, Koupal LR, Schwartz CD, Liesch JM, Hensens OD, Anderson PS, Freidinger R, Pettibone DJ. Oxytocin and vasopressin antagonists. Google Patents; 1992.Google Scholar
  8. Pettibone DJ, Clineschmidt BV, Anderson PS, Freidinger RM, Lundell GF, Koupal LR, Schwartz CD, Williamson JM, Goetz MA, Hensens OD, Liesch JM, Springer JP. A structurally unique, potent, and selective oxytocin antagonist derived from Streptomyces silvensis. Endocrinology. 1989;125:217–22.View ArticlePubMedGoogle Scholar
  9. Bock MG, DiPardo RM, Williams PD, Pettibone DJ, Clineschmidt BV, Ball RG, Veber DF, Freidinger RM. Receptor ligands which bind the oxytocin receptor with selectivity and high affinity. Chemical modification of a Streptomyces silvensis derived cyclic hexapeptide. J Med Chem. 1990;33:2321–3.View ArticlePubMedGoogle Scholar
  10. Williams PD, Bock MG, Tung RD, Garsky VM, Perlow DS, Erb JM, Lundell GF, Gould NP, Whitter WL, Hoffman JB, Kaufman MJ, Clineshcmidt BV, Pettibone DJ, Freidinger RM, Veber DF. Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural product. J Med Chem. 1992;35:3905–18.View ArticlePubMedGoogle Scholar
  11. Bock MG, Freidinger RM, Tung RD, Veber DF, Williams PD. Cyclic hexapeptide oxytocin antagonists. Google Patents; 1993.Google Scholar
  12. Williams PD, Anderson PS, Ball RG, Bock MG, Carroll L, Chiu SH, Clineschmidt BV, Culberson JC, Erb JM, Evans BE, Fitzpatrick SL, Freidinger RM, Kaufman MJ, Lundell GF, Murphy JS, Pawluczyk JM, Perlow DS, Pettibone DJ, Pitzenberger SM, Thompson KL, Veber DJ. 1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. J Med Chem. 1994;37:565–71.View ArticlePubMedGoogle Scholar
  13. Sirgel FA, Wiid IJ, van Helden PD. Measuring minimum inhibitory concentrations in mycobacteria. Methods Mol Biol. 2009;465:173–86.View ArticlePubMedGoogle Scholar
  14. Ioerger TR, O’Malley T, Liao R, Guinn KM, Hickey MJ, Mohaideen N, Murphy KC, Boshoff HI, Mizrahi V, Rubin EJ, Sassetti CM, Barry CE 3rd, Sherman DR, Parish T, Sacchettini JC. Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS ONE. 2013;8:e75245.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Ioerger TR, Feng YA, Ganesula K, Chen X, Dobos KM, Fortune S, Jacobs Wr J, Mizrahi V, Parish T, Rubin E, Sassetti C, Sacchettini JC. Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories. J Bacteriol. 2010;192:3645–53.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

Advertisement